SCTX · Scribe Therapeutics, Inc. · Investor Relations
$17.10
+0.90 (+5.56%)
At close · Nov 4
Return incl. dividend (before tax)
Going-concern doubt
— cleared Sep 2, 2026
The latest filing states the doubt was alleviated.
“Substantial doubt about our ability to continue as a going concern existed as of June 30, 2026 and was alleviated as a result of the completion of our initial public offering and concurrent private placement, which resulted in aggregate net proceeds of approximately $140.7 million.”View the 10-Q filed Sep 2, 2026
Market Cap
$320.27M
Shares
18.93M
Volume · Nov 4
204.81K
Avg daily vol (3M)
375.75K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-09-02 | Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-01-14 | J.P. Morgan 44th Annual Healthcare Conference | Conference |
| 2025-09-17 | Bank of America Healthcare Trailblazers Private Company Conference | Conference |
| 2025-03-11 | Leerink Partners Global Healthcare Conference | Conference |
| 2025-01-13 | J.P. Morgan 43rd Annual Healthcare Conference | Conference |
Source: https://investors.scribetx.com/